ADAC Labs
This article was originally published in The Gray Sheet
Executive Summary
Restatement of FYs 1996-98 (ended Sept. 27, 28 and 29, respectively) financial results reflects a reduction of the acquired in-process R&D booked in conjunction with the acquisition of Cortet in FY 1997, as well as "a more stringent revenue recognition policy than...in the past," the nuclear medicine/radiology systems manufacturer announces March 1 in reporting first quarter FY 1999 results. For the three months ended Jan. 3, revenues were $94.3 mil., up 40% over restated earnings one year earlier., while net income rose 14.7% to $3.9 mil., including non-ordinary restructuring and auditing charges of $4.1 mil. On Feb. 24, the Federal Accounting Standards Board ruled that all acquired in-process R&D be recognized an asset and amortized over its useful life ("The Gray Sheet" March 1, In Brief)
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.